Zoetis Inc. or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Zoetis Inc. or Iovance Biotherapeutics, Inc.?

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Zoetis Inc. and Iovance Biotherapeutics, Inc. have shown contrasting approaches to handling these costs.

From 2014 to 2023, Zoetis Inc. consistently reported higher SG&A expenses, averaging around $1.7 billion annually. Despite this, their expenses grew by only 31% over the period, indicating a stable cost management strategy. In contrast, Iovance Biotherapeutics, Inc. saw a staggering 1,043% increase in SG&A expenses, from approximately $9 million in 2014 to over $106 million in 2023. This rapid growth reflects their aggressive expansion and investment in administrative capabilities.

While Zoetis Inc. demonstrates steady control over its SG&A costs, Iovance's rising expenses highlight their dynamic growth phase. Investors and stakeholders should consider these trends when evaluating each company's financial health and strategic direction.